Entering the endgame for advanced RCC?

Affiliations

Comment

Louise Stone. Nat Rev Urol. 2022 Jan.

. 2022 Jan;19(1):4.

doi: 10.1038/s41585-021-00547-0.

No abstract available

Comment on

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial.
Regan MM, Jegede OA, Mantia CM, Powles T, Werner L, Motzer RJ, Tannir NM, Lee CH, Tomita Y, Voss MH, Plimack ER, Choueiri TK, Rini BI, Hammers HJ, Escudier B, Albiges L, Huo S, Del Tejo V, Stwalley B, Atkins MB, McDermott DF. Regan MM, et al. Clin Cancer Res. 2021 Dec 15;27(24):6687-6695. doi: 10.1158/1078-0432.CCR-21-2283. Epub 2021 Nov 10. Clin Cancer Res. 2021. PMID: 34759043 Free PMC article.
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920.
Emamekhoo H, Olsen MR, Carthon BC, Drakaki A, Percent IJ, Molina AM, Cho DC, Bendell JC, Gordan LN, Rezazadeh Kalebasty A, George DJ, Hutson TE, Arrowsmith ER, Zhang J, Zoco J, Johansen JL, Leung DK, Tykodi SS. Emamekhoo H, et al. Cancer. 2022 Mar 1;128(5):966-974. doi: 10.1002/cncr.34016. Epub 2021 Nov 16. Cancer. 2022. PMID: 34784056 Free PMC article. Clinical Trial.

1. Regan, M. M. et al. Treatment-free survival after immune checkpoint inhibitor therapy versus targeted therapy for advanced renal cell carcinoma: 42-month results of the CheckMate 214 trial. Clin. Cancer Res. https://doi.org/10.1158/1078-0432.CCR-21-2283 (2021) - DOI - PubMed
1. Emamekhoo, H. et al. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920. Cancer https://doi.org/10.1002/cncr.34016 (2021) - DOI - PubMed